期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Survivin与VEGF在类风湿关节炎发病机制中的研究进展 被引量：7

下载PDF
导出
摘要 类风湿关节炎（rheumatoid arthritis,RA）是一种常见的全身性自身免疫性疾病,以滑膜的异常增生和血管翳形成并侵入关节软骨造成骨和关节软骨破坏为特征。关于RA发病机制的探究一直处在不断的发展中,近年来对RA患者的滑膜组织异常增生做相应分析，表明RA滑膜细胞具有凋亡不足的特点，滑膜细胞异常凋亡及病理性血管新生可能在RA的发生和发展过程中起着关键的作用。
作者 马莎 林俊 晋松 李芹 张虹
机构地区 云南省第一人民医院风湿免疫科
出处 《重庆医学》 CAS 北大核心 2015年第4期541-543,共3页 Chongqing medicine
基金 云南省科技厅昆明医科大学联合专项基金(2011FB215)
关键词 关节炎 类风湿 血管内皮生长因子 存活素
分类号 R593.22 [医药卫生—内科学]
  • 相关文献

参考文献22

  • 1Orozco.G,Eyre S,Hinks A,et al.Study of the commongenetic background for rheumatoid arthritis and systemiclupus erythematosus[J J.Ann Rheum Dis,2011,70(3):463-468.
  • 2Xu K,Xu P,Yao JF,et al.Reduced apoptosis correlateswith enhanced autophagy in synovial tissues of rheuma-toid arthritis[J],Inflamm Res,2013,62(2):229-237.
  • 3Lee H,Kashiwakura J,Matsuda A,et al.Activation of hu-man synovial mast cells from rheumatoid arthritis or oste-oarthritis patients in response to aggregated IgG through Fcy receptor I and Fcy receptor II[J].ArthritisRheum,2013,65(1):109-119.
  • 4Kelly RJ,Lopez-Chavez A,Citrin D,et al.Impacting tumorcell-fate by targeting the inhibitor of apoptosis protein sur-viving[J].Mol Cancer,2011,10:35.
  • 5Szafer-Glusman E,Fuller MT,Giansanti MG.Role of Sur-vivin in cytokinesis revealed by a separation-of-functionallele[J].Mol Biol Cell,2011,22(20):3779-3790.
  • 6Svensson B,Hafstrom I,Forslind K,et al.Circulating sur-vivin,a novel and independent predictor of joint destruc-tion in early rheumatoid arthritis[J].Ann Rheum Dis,2007,66(20):523-530.
  • 7Bokarewa M,Lindblad S,Bokarew,et al.Balance betweensurvivin,a key member of the apoptosis inhibitor family,and its specific antibodies determines erosivity in rheuma-toid arthritis[J].Arthritis Res Ther,2005,7(5):349-358.
  • 8O'Connor DS,Schechner JS?Adida C,et al.Control of ap-optosis during angiogenesis by survivin expression in en-dothelial cells[J].Am J Pathol,2000,156(2):393-398.
  • 9Hyman BT,Yuan J.Apoptotic and non-apoptotic roles ofcaspases in neuronal physiology and pathophysiology[J].Nat Rev Neurosci,2012,13(6):395-406.
  • 10Anderson EJ,Rodriguez E,Anderson CA,et ai.Increasedpropensity for cell death in diabetic human heart is media-ted by mitochondrial-dependent pathways[J].Am J Phys-iol Heart Circ Physiol,2011,300(1):H118-H124.

同被引文献66

  • 1Burkhard Kloesch,Tatjana Becker,Elisabeth Dietersdorfer,Hans Kiener,Guenter Steiner.Anti-inflammatory and apoptotic effects of the polyphenol curcumin on human fibroblast-like synoviocytes[J]. International Immunopharmacology . 2013 (2)
  • 2KLOESCH B, BECKER T, DIETERSDORFER E, et al. Anti-inflammatory and apoptotic effects of the polyphenol curcumin on human fibroblast-like synoviocytes[J]. Int Immunopharmacol, 2013, 15(2): 400-405.
  • 3AZIZI G, BOGHOZIAN R, MIRSHAFIEY A. The potential role of angiogenic factors in rheumatoid arthritis[J]. Int J Rheumat Dis, 2014, 17(4): 369-383.
  • 4ZHU Z, YIN Y, ZHENG K, et al. Evaluation of synovial angiogenesis in patients with rheumatoid arthritis using 68Ga-PRGD2 PET/CT: a prospective proof of concept cohort study[J]. Ann Rheum Dis, 2014, 73(6): 1269-1272.
  • 5KIM S J, CHEN Z, CHAMBERLAIN N D, et al. Angiogen-esis in rheumatoid arthritis is fostered directly by toll-like receptor 5 ligation and indirectly through interleukin-17 induction[J]. Arthritis Rheum, 2013, 65(8): 2024-2036.
  • 6LUO Q, SUN Y, LIU W, et al. A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide[J]. J Immunol, 2013, 191(10): 4969-4978.
  • 7HU W, XIA L J, CHEN F H, et al. Recombinant human endostatin inhibits adjuvant arthritis by down-regulating VEGF expression and suppression of TNF-α, IL-1β production[J]. Inflamm Res, 2012, 61(8): 827-835.
  • 8MARUOTTI N, CANTATORE F P, RIBATTI D. Putative effects of potentially anti-angiogenic drugs in rheumatic diseases[J]. Eur J Clin Pharmacol, 2014, 70(2): 135-140.
  • 9HARA M, ISHIGURO N, KATAYAMA K, et al. Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial[J]. Mod Rheumatol, 2014, 24(3): 410-418.
  • 10MUCKE H A. Iguratimod: a new disease-modifying antirheu-matic drug[J]. Drugs Today(Barc), 2012, 48(9): 577-586.

引证文献7

二级引证文献58

重庆医学
2015年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部